Clinical Trials in San Antonio

Showing 3601-3620 of 12,572 trials

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

NCT04600466

This protocol is a single-institution feasibility study to identify the molecular and epidemiological risk factors in the development of gastric cancer in high-risk predominantly Hispanic South Texas population. The study is broken down into two main parts: 1) To identify molecular differences in gastric adenocarcinoma (GAC) between Non-Hispanics and Hispanics, stratified by age, and in benign, pre-malignant, and malignant gastric lesions; and 2) To identify environmental and clinicopathological factors in Hispanics associated with specific molecular changes linked to the development of GAC.

Gastric Cancer

The University of Texas Health Science Center at San Antonio150 participantsStarted Jan 2021

San Antonio, Texas, United States

COMPLETEDPhase 1/2< 1 mile

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD \[adults ≥ 65 years of age only\], or RIV4) in adults 18 years of age and older.

Influenza Immunization

Sanofi Pasteur, a Sanofi Company682 participantsStarted Nov 2022

Huntington Park, California, United States • Long Beach, California, United States • North Hollywood, California, United States +22 more locations

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Find Trials by Condition in San Antonio

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

SNV1521 in Participants with Advanced Solid Tumors

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

A Study of LY3561774 in Participants With Mixed Dyslipidemia

Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

Infant Mortality Reduction by the Mass Administration of Azithromycin